TransMedics Group (NASDAQ:TMDX) Director Sells $722,377.44 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director Thomas Gunderson sold 9,624 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

TransMedics Group Price Performance

TransMedics Group stock opened at $78.79 on Friday. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. The company’s 50-day moving average is $83.39 and its 200-day moving average is $112.79. The firm has a market capitalization of $2.72 billion, a PE ratio of 17.91 and a beta of 1.91. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The business had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.70 EPS. Sell-side analysts anticipate that TransMedics Group, Inc. will post 1.98 earnings per share for the current year.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently made changes to their positions in TMDX. Pacer Advisors Inc. lifted its holdings in TransMedics Group by 79.8% during the 1st quarter. Pacer Advisors Inc. now owns 2,391 shares of the company’s stock worth $238,000 after purchasing an additional 1,061 shares during the last quarter. Militia Capital Management LLC acquired a new position in TransMedics Group in the 1st quarter valued at $2,088,000. Janus Henderson Group PLC grew its holdings in TransMedics Group by 2.1% in the 1st quarter. Janus Henderson Group PLC now owns 73,488 shares of the company’s stock valued at $7,306,000 after buying an additional 1,537 shares in the last quarter. Amundi increased its position in TransMedics Group by 31.2% during the 1st quarter. Amundi now owns 6,897 shares of the company’s stock worth $686,000 after buying an additional 1,640 shares during the period. Finally, California State Teachers Retirement System increased its position in TransMedics Group by 22.8% during the 1st quarter. California State Teachers Retirement System now owns 37,840 shares of the company’s stock worth $3,762,000 after buying an additional 7,019 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on TMDX shares. UBS Group reissued a “hold” rating on shares of TransMedics Group in a report on Tuesday, May 26th. TD Cowen cut their price target on TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Needham & Company LLC reduced their price objective on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a report on Tuesday, June 9th. Finally, Piper Sandler dropped their price objective on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $134.50.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.